Ocuphire Pharma Inc. Stock
Ocuphire Pharma Inc. Stock
There is an upward development for Ocuphire Pharma Inc. compared to yesterday, with an increase of €0.080 (2.520%).
Our community identified positive and negative aspects for Ocuphire Pharma Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Ocuphire Pharma Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Ocuphire Pharma Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ocuphire Pharma Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc. | 2.520% | 4.348% | -2.890% | 269.231% | 99.762% | -13.625% | -20.755% |
| Actinium Pharmaceuticals Inc. | 17.090% | 10.015% | -13.139% | -45.161% | -40.845% | -87.795% | -87.018% |
| NanoViricides Inc. | 1.740% | -8.000% | -12.214% | -11.538% | 23.656% | -1.709% | -64.018% |
| AnaptysBio Inc | -0.530% | 4.692% | -14.603% | 191.353% | 15.186% | 187.965% | 147.650% |
Comments
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
